INTRODUCTION
Background and rationale Schizophrenia, characterised by hallucination, delusion, disorganised thinking and negative symptoms, is a chronic and disabling mental disorder which is commonly associated with impairment in social and occupational functioning. 1 Though schizophrenia cannot be cured, most people with schizophrenia can be effectively treated for symptoms with antipsychotic medicines. 2 
Strengths and limitations of this study
▪ The application of mobile health is designed not as a stand-alone technological solution but as a health system strengthening tool that serves to integrate the patient care provided by lay health supporters, village doctors, mental health administrators and psychiatrists. ▪ The active engagement of family members augments case supervision. ▪ The study, evaluating the real-world effectiveness of LEAN (Lay health supporter, e-platform, award, and iNtegration), emphasises the implementation parts so as to increase the likelihood of scaling up the potentially effective solution. ▪ The trial is intent on having global implications, especially insofar as the intervention is designed to exclude elements peculiar to China's socioeconomic and/or political situation. ▪ The short duration may not allow sufficient assessment of functional changes and limit analysis of the long-term effect on adherence. ▪ The choice of relatively simple assessment tools (pill counts vs urinalysis) may create challenges of obtaining an accurate adherence level. ▪ Assuming that improved medication adherence will lead to better patient life functioning may be problematic.
However, of the treated patients, 50% are non-adherent with medication; 3 moreover, even under conditions of compliance, 50% of patients suffer relapse within 1 year of their latest episode. 4 The '686' Program, a massive coutrywide government effort in China, is a relatively inexpensive and practical model that provides community-based mental healthcare with limited human and financial resources. 5 6 However, the programme faces the challenges of poor medication adherence and high relapse-26% of the programme participants never, 39% intermittently, and only 35% regularly take the prescribed medications. 7 This research aims to develop and evaluate a financially and operationally feasible and sustainable intervention (with the acronym LEAN (Lay health supporter, e-platform, award, and iNtegration)) to address those '686' programme challenges.
Hypothesis
We hypothesise that the LEAN plus '686' solution, as compared to the present '686' standard of care only, will improve medication adherence, reduce the incidence of schizophrenia symptoms, and ultimately result in improved social and occupational functioning for enrollees.
STUDY SETTING
The intervention will be implemented and tested in '686' programme participants in the Xiang dialect area (a total of 9 towns) of the rural townships of Liuyang Municipality in the Hunan province of China, with an intent to produce solutions that can be adapted and applied in other low and middle income countries (LMCs) with limited mental health resources. Liuyang has developed a three-tier '686' model extending from Liuyang Mental Health Hospital (MHH) to township health centres to village clinics that consist of five components: (1) patient screening by village doctors (VDs) and mental health administrators (MHAs); (2) MHAs registering the confirmed cases to the "686" programme; (3) Psychiatrists touring townships to provide free consultation and medication every 2 months ('bi-monthly visits'); (4) case management by MHA; and (5) regular monitoring by VDs [8] [9] [10] (figure 1). We should note that while Liuyang provides free antipsychotics to all its programme enrollees, in other parts of China, often only a subset of the programme participants receive free medication.
LEAN
LEAN as an acronym is somehow inspired by Toyota's principle in lean manufacturing, 11 although our focus is on adding value, minimising waste, and maintaining simplicity throughout programme implementation. The acronym LEAN summarises the critical components of the proposed intervention (figure 2). The LEAN participants can opt out of LEAN anytime by texting us or by informing VDs, MHAs by phone or in person.
Lay health supporter For each patient in the intervention, LEAN will identify an LHS-a member of the patient's family if possible or a community volunteer (such as a member of the village senior club)-who will perform simple but important roles in support of the patient: (1) facilitate patient medication adherence with prompts from the e-reminders, (2) monitor for early signs of relapse and for medication side effects using checklists from the e-monitor, and (3) team up with the VD and the township MHA to facilitate treatment adjustments and, if needed, emergent hospital care.
E-platform
The e-platform employs three main modules: The e-reminder sends the patient up to two reminders either by text or voice messages at 15 min interval until the patient responds with confirmation that the scheduled medication has been taken. Failure to send a confirmation will trigger up to two text alerts to the patient's LHS, prompting the LHS to check in with the patient and text back the result. The e-monitor assists LHSs and patients in detecting signs of relapse and monitoring medication side effects using relevant checklists texted to the patient and LHS at regular intervals (see relapse checklist in the online supplementary appendix). Finally, the e-educator will send periodic SMS messages to the patient, LHS, MHA and VD to educate them on schizophrenia symptoms, medication, adherence strategies, relapse, rehabilitation and social resources.
Award system
Patients and LHSs will accumulate points for responding to SMS messages. Each of their texted confirmations back to the LEAN system will accumulate one point, which will be recorded automatically by the computer system. The points, counted every 2 months, will advance their Taekwondo-like belt ranking and entitle them to a small gift of US$2-3 such as soap bars when they come for the bimonthly visit to be presented by a LEAN programme staff member.
iNtegration
The efforts of the patient and LHS to improve medication adherence and reduce relapses will be integrated and facilitated by the e-platform with those of the VD, MHA and psychiatrist so that the innovations of LEAN strengthen the existing health system. With this integration, non-adherence and relapses detected can then be actually handled with LHSs, VDs, MHAs and psychiatrists taking concerted effort for prompt treatment adjustments or referrals for emergent hospitalisation.
Mechanism of LEAN
The mechanism of LEAN medication adherence is based on an adapted health belief model (HBM) (figure 3). 12 13 According to this theory, people with schizophrenia make their medication adherence decisions based on push ( patients' self-motivation in improving health) and pull factors that include three elements: (1) patients' perception of the threat posed by schizophrenia; (2) patients' perceived net benefit of adhering to therapy, a calculation involving the benefits of therapy minus costs; and (3) action cues such as the aforementioned e-reminders or mass media health promotion campaigns. Figure 3 illustrates the interface of various LEAN elements with the components of the HBM.
The development of LEAN has been guided by the HBM as a theoretical framework, as well as informed by empirical evidence, particularly in the areas of human resources for health (HRH) and mobile health (mHealth). Much of the literature in HRH suggests that 'task shifting'-cascading appropriate tasks from more skilled psychiatrists to less specialised MHAs/VDs and to LHSs-improves access and efficacy when HRH are lacking or deficient 14 15 (Liuyang has only 1.35 psychiatrists/1.42 specialist nurses vs 8.59 psychiatrists/29.15 nurses for high-income countries per 100 000 population in 2011). The e-platform facilitates efficient communication and integration of this network of human resources. Moreover, much evidence supports the use of reminders to improve medication adherence. [16] [17] [18] [19] [20] STUDY POPULATION AND THE LEAN SAMPLE People in Liuyang speak three distinct dialects: Gan, Xiang and Hakka. The Xiang dialect area, located in the west of Liuyang municipality, has 9 townships, 98 villages and a population of 356 900. The '686' Program maintains a roster of patients with schizophrenia in the Xiang dialect area of Liuyang municipality (total: 631 in 2011) (figure 4), which forms the study population. The characteristics of this population, most relevant to our study, are summarised in table 1. The Xiang dialect population is selected due to (1) the efficiency to recruit, train and collect data in a more focused population; (2) the Xiang dialect group being the majority group in Hunan province while the other two dialect groups in Liuyang are historically immigrants from other provinces; and (3) the long and rich past research experience of our group in this area that provides additional data and information for the LEAN study, such as educational levels of all MHAs.
Inclusion and exclusion criteria
The following criteria more precisely define the study population by establishing eligibility requirements for subject recruitment. Since villagers and LHSs without a phone will be given a free basic phone and subscription plan, the phone ownership is not included in the inclusion or exclusion criteria. Rationales for inclusion and exclusion criteria are given in parentheses. Sampling frame, the LEAN sample and recruitment The most recent '686' Program registry of patients with schizophrenia will be used as the sampling frame, from which we aim to draw 258 patients as the LEAN sample.
To that end, a statistician otherwise not associated with the project will first create a recruitment list of 400 people drawn at random from the sampling frame. Assuming that 15% of those selected will prove ineligible and that a further 20% will elect not to participate, an initial list of 400 should ensure a final recruitment of no less than 258 participants. MHAs will provide an initial screening by cross-checking the recruitment list against their own records in order to verify eligibility. Recruitment by project staff will occur during patients' bimonthly medication refill visits, when psychiatrists will reconfirm the diagnoses of those on the list. Project staff will conduct home visits within 1 month of their expected bimonthly visit to recruit those not contacted at the refill visits. At the end of the recruitment, the LEAN sample will be randomly divided by the same statistician into a treatment group and a control group of equal sizes by a statistician not otherwise involved in the study ( figure 5 ).
Sample size calculation
Though the distribution of our primary outcome (adherence, scored as the percentage of drugs taken of those prescribed) is unlikely to be normally distributed, the sample calculation follows standard procedures for the hypothesis of equal population means based on t test and the comparison of sample means. Since our sample size is large, the central limit theorem ensures that our sample means will be approximately normally distributed, regardless of the underlying distribution of the data. Assuming a 5% type I error and a 10% dropout ratio for a total sample size of 258 (129 for each of the two comparison groups), the study of 232 participants (after 10% dropping out of 258) will have 85% power to detect an effect size of 0.13 (see online supplementary material appendices). This means that if the adherence score for the control group is 0.72 (SD=0.33), the study will have sufficient power to detect a programme effect if adherence for the treatment group is equal to or greater than 0.85. The control adherence of 0.72 used in the sample calculation is based on the self-reported adherence of 0.75 in our study population from the '686' registry.
The proposed sample size of 258 will also satisfy the power requirement for a subgroup analysis of patients who are non-adherent at baseline. Given the ratio of non-adherence to full adherence (0.55:0.45) of the population reported in the registry, the study will include at least 140 baseline non-adherent participants available for the subgroup analysis. Again, assuming 5% type I error and a 10% dropout rate, the study will have 85% power to detect an effect size of 0.18 among the subgroup: if the adherence rate for the control is 0.42 (SD=0.35), the study will be powered to detect a programme effect if the adherence of the treatment group is equal to or greater than 0.6 (table 2).
METRICS AND MEASUREMENT Primary and secondary outcomes
The primary outcome will be a continuous medication adherence score from 0 (no adherence) to 1 (complete adherence), calculated as the percentage of drugs taken out of those prescribed over a designated time period (the preceding month). Medication adherence was chosen as the primary outcome on the grounds that (1) adherence correlates with symptom relief, and symptoms correlate with function; 22 23 (2) significant improvement in symptoms and functions is likely to extend beyond the duration of the study; and (3) improving adherence is valuable in its own right. However, symptoms and functions will also be tracked as the secondary outcomes. Figure 6 summarises how and when we assess outcomes, which piggyback on '686' Program activities, in particular, the bimonthly meetings with patients. All data will be double-entered into and managed by the Research electronic data capture (REDCap) system. 24 All outcome assessors, including psychiatrists and programme staff, will be blinded to the control or treatment status of programme participants; any inadvertent unblinding will be noted in order to record the time of the incident and persons involved.
Methods of assessment and timeline

Medication adherence: pill counts
Pill counts, to be conducted by project staff when patients bring their pill bottles to the bimonthly refill, will be used as the primary, objective and inexpensive measurement of medication adherence, to be complemented by pharmacy dispensing records from the '686' registry system. Other objective measures, such as the serum/urine drug level, 25 are clinically and financially impossible to implement. In addition, the Morisky Medication Adherence Scale, 26 the Brief Adherence Rating Scale (BARS) 27 and the Drug Attitude Inventory-10 (DAI-10) 28 will supplement the objective assessment. At baseline and again at the end of the study, patients who were no-shows at the bimonthly visit will be visited and assessed at their homes.
Symptoms: Clinical Global Impression in Schizophrenia
From among the 'big three' instruments for schizophrenic symptoms, 29 we chose the Clinical Global Impression in Schizophrenia (CGI-Sch) primarily due to its brevity and ease of use. 30 '686' Program psychiatrists will assess patients using the CGI-Sch during bimonthly visits throughout the trial.
Functions: WHODAS 2.0 LEAN will use the 12-item proxy-administered WHO Disability Assessment Schedule 2.0 to assess patient functions. We select this instrument because of its brevity to administer, excellent psychometric properties and availability of a validated Chinese version. 31 32 Public health students enlisted as programme staff will administer the WHODAS to patients and their family members during bimonthly visits. 
Other measures
Since a side effect of anti-antipsychotics may relate to adherence, the brief and self-implemented Glasgow Antipsychotic Side-effect Scale (GASS) will be used to generate a side-effect score. 33 A few other 'public health' indicators such as suicide, drug abuse, attacking people, destroying things and wandering will be captured by the existing '686' registry. In addition, many process, cost and service utilisation indicators will be captured and recorded by the e-platform logs and '686' administrative registry. These process indicators will facilitate analysis of various links in the LEAN mechanism, and surveillance for breaks in the chain.
TRIAL DESIGN
We adopt a wait-list design with participants followed up for 6 months after launch of the intervention. The waitlist control design is increasingly used in psychotherapy studies, primarily to address the ethical dilemma involved in withholding a potentially beneficial treatment from the control group. Participants recruited into the study are randomised into a treatment group and a 'wait-listed' control group. In stage 1 (the 6-month period following programme initiation), the intervention will be applied to the intervention group only, while the wait-list group will receive usual care per the regular '686' protocol; in stage 2 (a subsequent 6-month period), the wait-list group will receive the intervention, having 'waited' through stage one. Analysis of the intervention will be conducted on the basis of the baseline and end point data collected on both groups during stage one only due to our budget constraints on data collection. Consequently, the only difference between a wait-list design and a traditional two-arm randomised control trial (RCT) is that the control group is also able to benefit from the treatment once the formal study is complete. 
MODEL AND ANALYSIS Unadjusted analysis, analysis of covariance and difference-in-difference
We mainly considered the issue of efficiency ( precision of the estimator) and bias in our choice of analytical methods. The literature suggests that analysis of covariance provides higher efficiency than differencein-difference and the unadjusted model in RCT and is the optimal model for RCT analysis 34 ( figure 7 ). The LEAN analysis will include as covariates the strong baseline predictors of outcome that are empirically suggested by other studies, and will comprise adherence, WHODAS and CGI-Sch scores, as well as indices of negative symptoms, substance use, medication side effects and family supervision. 35 It should be noted that while our response variable, expressed as an adherence score from 0 to 1, may yield values greater than one, those out-of-bound predictions do not invalidate the model since the study's purpose is to produce a 'risk difference' (difference in mean adherence between intervention and control groups) rather than an individual prediction. Critically, the large sample size and the central limit theorem ensure that this approach will yield valid inferences of the risk difference despite non-normal adherence outcomes.
Intent-to-treat
An intent-to-treat (IIT) analysis will be used to analyse all participants regardless of the treatment actually received. Estimating the IIT effect is more appropriate than the per-protocol or per-treat methods since the LEAN trial is a pragmatic trial, which is to say, it is meant to determine the effectiveness of LEAN as a realworld solution.
Subgroup analysis
We plan to conduct two subgroup analyses, both with a strong theory base and possible interaction effects. The first concerning the non-adherent group at baseline is sufficiently powered (table 2) (our adherence-focused intervention is more likely to work better for the initially non-adherent group). The other subgroup analyses will be conducted to assess level of functions.
Missing data
Reasons for missing data will be recorded. Multiple imputation methods will be used so that sensitivity analyses will be conducted to assess the robustness of trial results under different methods.
MONITORING
Considering the short duration of the intervention, we do not have a data monitoring committee. At the midpoint of the trial, outcomes and text messaging data will be analysed to detect any abnormality. The text messaging system also provides a means for ongoing monitoring of any patient response.
ETHICS AND DISSEMINATION
The study has obtained institution review board (IRB) approval from the University of Washington (49464 G) and Central South University (CTXY-150002-6). Any substantive modification to the protocol will seek a formal approval from the IRBs. Programme staff will train and obtain informed consent from both patients and LHSs. Patient data will be securely entered and stored in RedCap and only deidentified information will be used for analysis. Study results will seek peer-reviewed publications with deidentified data made available on Figshare. 36 
DISCUSSION
Several aspects of this study are worth noting. First, the application of mHealth is designed not as a standalone technological solution but as a health system strengthening tool that serves to integrate the patient care provided by lay health supporters (LHS), VDs, MHAs and psychiatrists. Figure 7 Three approaches to RCT analysis. Source: adapted from Siyuan Zhang's paper. 34 ANCOVA, analysis of covariance; DiD, difference-in-difference; RCT, randomised controlled trial.
Second, the active engagement of LHS augments case supervision. Third, the study, evaluating the real-world effectiveness of LEAN, emphasises the implementation parts so as to increase the likelihood of adopting the potentially effective solution. Fourth, the trial is intent on having global implications, especially insofar as the intervention is designed to exclude elements peculiar to China's socioeconomic and/or political situation.
The study is faced with several limitations. First, its short duration may not allow sufficient assessment of functional changes and limit analysis of the long-term effect on adherence. Second, our choice of relatively simple assessment tools ( pill counts vs urinalysis) may create challenges of obtaining accurate adherence levels. Third, assuming that improved medication adherence will lead to better patient life functioning may be problematic. There is concern that psychiatrists with limited training from Liuyang MHH may deliver inappropriate treatments, adherence to which will be of insufficient benefit. Finally, despite efforts to ensure the generalisability of LEAN, the existing '686' infrastructure ( particularly the availability of free basic antipsychotics and the bimonthly physiatrists' visit) may make Liuyang a unique location even within China. We hope that the spirit of LEAN will provide useful information for other LMCs. For instance, LEAN may be adapted to manage patients discharged from mental facilities who continue to take free or paid medications.
